Physician profile
Roberto Ruiz
NPI 1336471606
$3,866.68
in general payments reported to CMS, 2019-2025
31 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $426 · 2021: $731 · 2022: $16.67 · 2023: $258 · 2024: $561 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,692.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $813.96 | 2020-2025 | Farxiga, Airsupra |
| Amgen INC. | $491.09 | 2020-2025 | Tavneos, Repatha, Otezla |
| Novo Nordisk INC | $424.68 | 2020-2025 | Ozempic, Rybelsus, Saxenda |
| Abbott Laboratories | $347.25 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $168.08 | 2025 | |
| Sanofi-Aventis U.S. LLC | $165.70 | 2020-2021 | |
| Abbvie INC. | $156.44 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.50 | 2024-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $139.22 | 2024-2025 | Voquezna |
| Scpharmaceuticals INC. | $125.00 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $94.85 | 2020-2021 | |
| Eisai INC. | $86.34 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $84.67 | 2025 | Zenpep, Vowst |
| Allergan, INC. | $84.29 | 2020 | |
| Lilly USA, LLC | $82.89 | 2024-2025 | Mounjaro, Zepbound |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $75.07 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $60.50 | 2021 | |
| Ardelyx, INC. | $56.07 | 2024-2025 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $30.44 | 2021-2025 | Austedo Xr |
| Supernus Pharmaceuticals, INC. | $29.06 | 2021 | |
| Amarin Pharma, INC. | $27.41 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.32 | 2021 | |
| Astellas Pharma US INC | $22.80 | 2024 | Veozah |
| Tactile Systems Technology INC | $19.89 | 2024 | Entre Plus, Flexitouch Plus |
| Exact Sciences Corporation | $17.79 | 2025 | Cologuard Collection Kit |
| 3b Medical, INC. | $17.15 | 2025 | Luna |
| Biohaven Pharmaceutical Holding Company LTD. | $16.67 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.83 | 2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.01 | 2021 | |
| Antares Pharma, INC. | $14.80 | 2025 | Xyosted |
| Pfizer INC. | $13.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Ruiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.